Cargando…

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index

This study investigated the effects of switching from combination therapy with either alogliptin (Alo) or pioglitazone (Pio) to fixed-dose combination therapy (FDCT) with alogliptin and pioglitazone (Alo-Pio FDCT). The usefulness and efficacy of Alo-Pio FDCT were investigated. A total of 50 outpatie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoki, Chie, Suzuki, Kunihiro, Kuroda, Hisamoto, Sagara, Masaaki, Shimizu, Masanori, Kasai, Kikuo, Aso, Yoshimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nagoya University 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346615/ https://www.ncbi.nlm.nih.gov/pubmed/28303056 http://dx.doi.org/10.18999/nagjms.79.1.9

Ejemplares similares

Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study
por: Suzuki, Kunihiro, et al.
Publicado: (2017)

Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes
por: Suzuki, Kunihiro, et al.
Publicado: (2017)

Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
por: Matsumura, Mihoko, et al.
Publicado: (2017)

Erratum to: Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
por: Matsumura, Mihoko, et al.
Publicado: (2017)

Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin
por: Yin, Hao, et al.
Publicado: (2013)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study
por: Sagara, Masaaki, et al.
Publicado: (2016)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study
por: Takebayashi, Kohzo, et al.
Publicado: (2017)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Investigation of Alogliptin-Loaded In Situ Gel Implants by 2(3) Factorial Design with Glycemic Assessment in Rats
por: Ibrahim, Tarek M., et al.
Publicado: (2022)

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Effects of Twice-Daily Injections of Premixed Insulin Analog on Glycemic Control in Type 2 Diabetic Patients
por: Shimizu, Hiroaki, et al.
Publicado: (2010)

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice
por: Akita, Koji, et al.
Publicado: (2015)

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
por: Kashiwagi, Atsunori, et al.
Publicado: (2011)

Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro
por: Shigematsu, Nao, et al.
Publicado: (2020)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Liquid Chromatographic Determination of Alogliptin in Bulk and in its Pharmaceutical Preparation
por: El-Bagary, Ramzia I., et al.
Publicado: (2012)

Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis
por: Shima, Hisato, et al.
Publicado: (2019)

Necrotizing Pancreatitis Secondary to Hydrochlorothiazide and Alogliptin: A Case Report
por: Del Rio, Teresa, et al.
Publicado: (2023)

Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels
por: Ohashi, Naro, et al.
Publicado: (2014)

Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial
por: Ji, Linong, et al.
Publicado: (2017)

CDK14 Promotes Axon Regeneration by Regulating the Noncanonical Wnt Signaling Pathway in a Kinase-Independent Manner
por: Hisamoto, Naoki, et al.
Publicado: (2021)

Direct Inhibitory Effects of Pioglitazone on Hepatic Fetuin-A Expression
por: Ochi, Akinobu, et al.
Publicado: (2014)

Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
por: Kapoor, Shailendra
Publicado: (2012)

Alogliptin improves survival and health of mice on a high‐fat diet
por: Zhu, Biao, et al.
Publicado: (2019)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
por: Kaku, Kohei, et al.
Publicado: (2019)

Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
por: Mohanty, Dibyalochan, et al.
Publicado: (2022)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Treatment of Streptozotocin-Induced Diabetic Rats with Alogliptin: Effect on Vascular and Neural Complications
por: Davidson, Eric P., et al.
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis
por: Cai, Yuli, et al.
Publicado: (2017)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4tdgecf606s4r8uc8i0rjjb86h